Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
Saved in:
| Title: | Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. |
|---|---|
| Authors: | Crouch ER; Virginia Pediatric Eye Center, Virginia Beach., Kraker RT; Jaeb Center for Health Research, Tampa, Florida., Wallace DK; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis., Holmes JM; Mayo Clinic, Rochester, Minnesota., Repka MX; Wilmer Institute, Baltimore, Maryland., Collinge JE; Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City.; Now with Connecticut Children's Medical Center, Hartford, Connecticut., Bremer DL; Pediatric Ophthalmology Associates Inc, Columbus, Ohio., Gray ME; Cincinnati Children's Hospital, Cincinnati, Ohio., Smith HA; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis., Steinkuller PG; Texas Children's Hospital, Houston. |
| Corporate Authors: | Writing Committee for Pediatric Eye Disease Investigator Group |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2020 Jan 01; Vol. 138 (1), pp. 14-20. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
